Novai Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 13

Novai General Information

Description

Developer of retinal biomarker designed for drug development for Age-related macular degeneration (AMD) & glaucoma therapeutics. The company's platform is designed for early detection and treatment of ophthalmic diseases, enabling healthcare providers to improve patient outcomes through features like real-time disease activity assessment and targeted drug delivery.

Contact Information

Website
www.novai.co.uk
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9 Greyfriars Road
  • Berkshire
  • Reading RG1 1NU
  • England, United Kingdom
+44 020
Primary Industry
Other Devices and Supplies
Other Industries
Decision/Risk Analysis
Other Pharmaceuticals and Biotechnology
Vertical(s)
Artificial Intelligence & Machine Learning, Life Sciences
Corporate Office
  • 9 Greyfriars Road
  • Berkshire
  • Reading RG1 1NU
  • England, United Kingdom
+44 020

Novai Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novai Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Early Stage VC 18-Dec-2024 Completed Clinical Trials - Phase 1
10. Accelerator/Incubator Completed Clinical Trials - Phase 1
9. Accelerator/Incubator Completed Clinical Trials - Phase 1
8. Early Stage VC (Series A) 31-Aug-2023 Completed Clinical Trials - Phase 1
7. Grant 01-Jul-2022 Completed Clinical Trials - Phase 1
6. Seed Round 22-Nov-2021 Completed Clinical Trials - Phase 1
5. Seed Round 31-Mar-2021 Completed Clinical Trials - General
4. Grant 01-Feb-2021 Completed Clinical Trials - General
3. Equity Crowdfunding 01-Dec-2020 $198K $813K Completed Clinical Trials - General
2. Grant 01-Oct-2020 $170K $615K Completed Clinical Trials - General
To view Novai’s complete valuation and funding history, request access »

Novai Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary A
Ordinary A
Ordinary A
Ordinary A 56,254 $0.000013 $21.95 $21.95 1x $21.95 9.37%
Ordinary A 41,667 $0.000013 $15.24 $15.24 1x $15.24 6.94%
To view Novai’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Novai Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of retinal biomarker designed for drug development for Age-related macular degeneration (AMD) & glaucoma thera
Other Devices and Supplies
Reading, United Kingdom
13 As of 2025

Vienna, Austria
 

Los Angeles, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novai Competitors (2)

One of Novai’s 2 competitors is RetInSight, a Corporation company based in Vienna, Austria.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
RetInSight Corporation Vienna, Austria
Eyenuk Venture Capital-Backed Los Angeles, CA
You’re viewing 2 of 2 competitors. Get the full list »

Novai Patents

  • 6

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Novai Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202019109-D0 Marker for use in identifying or predicting angiogenesis Inactive 03-Dec-2020
CA-3200936-A1 Marker for use in identifying or predicting angiogenesis Pending 03-Dec-2020
AU-2021392993-A1 Marker for use in identifying or predicting angiogenesis Pending 03-Dec-2020
EP-4255505-A1 Marker for use in identifying or predicting angiogenesis Pending 03-Dec-2020
JP-2023551999-A Markers for use in identifying or predicting angiogenesis Pending 03-Dec-2020 A61K49/0056
To view Novai’s complete patent history, request access »

Novai Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novai Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Active Capital (London) Venture Capital Minority
No Label Ventures Venture Capital Minority
Telarik Venture Capital Minority
The FSE Group Venture Capital Minority
Anglia Capital Group Angel Group Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

Novai FAQs

  • When was Novai founded?

    Novai was founded in 2020.

  • Where is Novai headquartered?

    Novai is headquartered in Reading, United Kingdom.

  • What is the size of Novai?

    Novai has 13 total employees.

  • What industry is Novai in?

    Novai’s primary industry is Other Devices and Supplies.

  • Is Novai a private or public company?

    Novai is a Private company.

  • What is Novai’s current revenue?

    The current revenue for Novai is .

  • How much funding has Novai raised over time?

    Novai has raised $6.14M.

  • Who are Novai’s investors?

    Active Capital (London), No Label Ventures, Telarik, The FSE Group, and Anglia Capital Group are 5 of 13 investors who have invested in Novai.

  • Who are Novai’s competitors?

    RetInSight and Eyenuk are competitors of Novai.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »